Online Purchasing Account You are logged on as Guest. LoginRegister a New AccountShopping cart (Empty)
United States 

Targeting Epigenetic Proteins to Prevent Breast Cancer

Breast cancer can occur in both women and men, and arises from the proliferation of abnormal cells. Mammary glands contain two types of cells, basal and luminal, which are formed from specialized stem or progenitor cells. The sex hormone, progesterone, can surge and induce these cells to increase mammary gland formation during pregnancy or menstruation. Epigenetic proteins can trigger stem cell proliferation in response to the increased levels of progesterone. Unfortunately, progesterone has been linked to the development of breast cancer. The number of progenitor cells is often higher in women carrying BRCA1 mutations and other genes that increase the risk of developing cancer. At this time, there are no standard preventative strategies targeting stem and progenitor cells for women at high risk of cancer.

A recent report suggests epigenetic proteins promote the proliferation of mammary gland stem cells in response to progesterone. Researchers isolated cells from the mammary glands of mice and examined the effects of exposure to progesterone. Protein levels were quantified, which indicated upregulation of epigenetic regulatory proteins that can modify chromosomes. Multiple epigenetic inhibitors that inhibited the proliferation of mammary gland progenitor cells, including FDA approved drugs, were tested. One drug, decitabine, that inhibits DNA methyltransferase enzymes, was found to reduce tumor development in cancer-prone rodents. Furthermore, progenitor cells from BRCA1 mutation patients were shown to be vulnerable to epigenetic inhibitors. Targeted drug inhibition of epigenetic proteins could prevent the development of breast cancer in women with a high risk of the disease.

For more information:

Enzo Life Sciences provides a wide variety of products for your Epigenetics and Cancer research needs. Our platforms provide a wide range of small molecules, antibodies, and proteins. Our FLUOR DE LYS® HDAC & Sirtuin assay platform has freed researchers from cumbersome protocols for screening HDAC & Sirtuin activity. Our high-quality chemiluminescent, fluorescent, and colorimetric assays deliver more high-quality hits, and are backed by a broad panel of characterized inhibitors and PTM-specific antibodies for ubiquitinylation, sumoylation, methylation, acetylation, and phosphorylation. Enzo offers the SCREEN-WELL® Cancer Library, a collection of 275 compounds that can be used for screening and assay development. All of the compounds in our SCREEN-WELL® FDA v. 2.0 Approved Drug Library have known and well-characterized bioactivity, safety and bioavailability - properties which could dramatically accelerate drug development and optimization.

Never miss a new TechNote!

Receive our TechNotes as soon as they are published.

comments powered by Disqus

Follow Us!


Related Products

SCREEN-WELL® Cancer Library 

Essential standards for cancer inhibitor screening
HTS | Print as PDF
ENZ-LIB102-0100 1 Library 100 µl/well 6,574.00 USD
Do you need bulk/larger quantities?

SCREEN-WELL® FDA approved drug library V2 

Accelerates drug optimization with a unique collection of compounds of known safety and bioavailability for diverse targets.
HTS | Print as PDF
BML-2843-0100 1 Library 100 µl/well 10,114.00 USD
Do you need bulk/larger quantities?

FLUOR DE LYS® HDAC fluorometric activity assay kit 

First-to-market by the leader in Epigenetics research tools
Fluorescent detection, HTS, Activity assay | Print as PDF
BML-AK500-0001 96 wells 638.00 USD
Do you need bulk/larger quantities?

FLUOR DE LYS® SIRT1 fluorometric drug discovery assay kit 

First-to-market by the leader in Epigenetics research tools
Fluorescent detection, HTS, Activity assay, Cell-based assays | Print as PDF
BML-AK555-0001 96 wells 849.00 USD
Do you need bulk/larger quantities?


Antioxidant. SIRT1 activator.
501-36-0, ≥98% (HPLC) | Print as PDF
BML-FR104-0100 100 mg 73.00 USD
BML-FR104-0500 500 mg 321.00 USD
Do you need bulk/larger quantities?

Triacetyl resveratrol 

SIRT activator
42206-94-0, Synthetic., ≥98% (TLC) | Print as PDF
BML-FR119-0010 10 mg 87.00 USD
Do you need bulk/larger quantities?

SCREEN-WELL® Wnt Pathway library 

Compounds are highly relevant; many are unique
HTS | Print as PDF
BML-2838-0100 1 Library 100 µl/well 1,882.00 USD
BML-2838-0500 1 Library 500 µl/well 4,507.00 USD
Do you need bulk/larger quantities?

SCREEN-WELL® Autophagy library 

Structurally and mechanistically different compounds for studying the roles of pro- and anti-autophagic molecules in cells and in vitro applications.
HTS | Print as PDF
BML-2837-0100 1 Library 100 µl/well 1,386.00 USD
BML-2837-0500 1 Library 500 µl/well 3,559.00 USD
Do you need bulk/larger quantities?


AMPK inhibitor
866405-64-3, ≥98% (TLC) | Print as PDF
BML-EI369-0005 5 mg 114.00 USD
BML-EI369-0025 25 mg 471.00 USD
Do you need bulk/larger quantities?


S6 kinase inhibitor
501437-28-1, ≥98% (HPLC) | Print as PDF
BML-EI407-0001 1 mg 90.00 USD
BML-EI407-0005 5 mg 267.00 USD
Do you need bulk/larger quantities?

PD-1 (human), (recombinant) 

Produced in HEK cells. Extracellular domain of PD-1 (aa 25-167) containing a 5’-His-tag, V5 epitope tag spacer, and a FLAG-tag., ≥90% (SDS-PAGE) | Print as PDF
ENZ-PRT190-0050 50 µg 395.00 USD
Do you need bulk/larger quantities?

PD-L1 (human), (recombinant) 

Produced in HEK cells. Human PD-L1 (aa 19-239) is fused at the N-terminus to a His-tag and FLAG®-tag., ≥90% (SDS-PAGE) | Print as PDF
ENZ-PRT223-0100 100 µg 619.00 USD
Do you need bulk/larger quantities?

MEGACD40L® Protein (soluble) (human), (recombinant) 

High activity, high purity CD40L protein for co-stimulatory activation of an immune response
Produced in CHO cells. The extracellular domain of human CD40L (CD154) (aa 116-261) is fused at the N-terminus to mouse ACRP30headless (aa 18-111) and a FLAG®-tag., ≥90% (SDS-PAGE) | Print as PDF
ALX-522-110-C010 10 µg 670.00 USD
Do you need bulk/larger quantities?

Recommend this page